SCHEMBL994567

SCHEMBL994567

O=C(O)c1ccc(N2CCN(c3ccccn3)CC2)nn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.53
KDM4E B2RXH2 7/20 0.53
HPGD P15428 2/20 0.53
HSD17B10 Q99714 2/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2C9 P11712 1/20 0.53
RECQL P46063 1/20 0.53
ADRB2 P07550 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.52
MAPK1 P28482 1/20 0.52
SLC6A7 Q99884 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
HTR1A P08908 1/20 0.51
LMNA P02545 1/20 0.50
TSHR P16473 1/20 0.50
THRB P10828 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
POLB P06746 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2942282 0.85 L3MBTL1 (0.64) ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2
SCHEMBL64557 0.78 NPC1 (0.47) ALDH1A1KDM4EL3MBTL1LMNA
SCHEMBL936603 0.78 SLC6A7 (0.55) ALDH1A1KDM4ESMN1; SMN2MAPK1SLC6A7
SCHEMBL20021209 0.78 CYP1A2 (0.53) ALDH1A1HPGDLMNAPOLB
SCHEMBL937146 0.77 DRD4 (0.50) ALDH1A1SMN1; SMN2L3MBTL1LMNAKMT2A
SCHEMBL995031 0.77 HSD11B1 (0.59) ALDH1A1MAPK1NPSR1KMT2A
SCHEMBL21353591 0.77
SCHEMBL15800694 0.77 PLD1 (0.73) ALDH1A1KDM4EHPGDHSD17B10CYP3A4
SCHEMBL29857922 0.77 PLD1 (0.73) ALDH1A1KDM4EHPGDHSD17B10CYP3A4
SCHEMBL1459007 0.76 ALDH1A1 (0.68) ALDH1A1KDM4EHPGDHSD17B10CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1804799-B1 Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors XENON PHARMACEUTICALS INC (CA) 2013-08-21 EP claimed
US-7592343-B2 Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors XENON PHARMACEUTICALS INC. (CA) 2009-09-22 US claimed
US-20080125434-A1 Heterocyclic Derivatives and Their Use as Strearoyl-Coa Desaturase Inhibitors XENON PHARMACEUTICALS INC. (CA) 2008-05-29 US claimed
EP-1804799-A2 HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2007-07-11 EP claimed
WO-2006101521-A2 HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2006-09-28 WO claimed
EP-1804799-B1 Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors XENON PHARMACEUTICALS INC (CA) 2013-08-21 EP disclosed
US-8026360-B2 Substituted pyridazines as stearoyl-CoA desaturase inhibitors XENON PHARMACEUTICALS INC. (CA) 2011-09-27 US disclosed
EP-2269610-A2 Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors Xenon Pharmaceuticals Inc. (CA) 2011-01-05 EP disclosed
US-20090306090-A1 HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2009-12-10 US disclosed
US-7592343-B2 Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors XENON PHARMACEUTICALS INC. (CA) 2009-09-22 US disclosed
US-20080125434-A1 Heterocyclic Derivatives and Their Use as Strearoyl-Coa Desaturase Inhibitors XENON PHARMACEUTICALS INC. (CA) 2008-05-29 US disclosed
EP-1804799-A2 HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2007-07-11 EP disclosed
WO-2006101521-A2 HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125434-A1 Heterocyclic Derivatives and Their Use as Strearoyl-Coa Desaturase Inhibitors SCD, SCD5, NR1H2 ALDH1A1 1019/4885KDM4E 901/4885HPGD 374/4885
US-20090306090-A1 HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS SCD, SCD5, FADS2 ALDH1A1 1678/4885KDM4E 516/4885HPGD 288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.